(Alliance News) - Futura Medical PLC on Wednesday said the Mexican Secretariat of Health has granted over the counter sale marketing authorisation for its erectile dysfunction topical gel formulation Eroxon.
The Guildford, Surrey-based pharmaceutical company firm said Eroxon, the brand name for MED3000, can now be marketed in Mexico as a topical treatment for erectile dysfunction available over the counter without the need for a prescription.
Futura Medical said Eroxon has already been approved as the first pan-European clinically proven topical over the counter treatment for erectile dysfunction and is now available in a growing number of EU and Middle East markets.
Initial launches began under the Eroxon brand name in March 2023, Futura Medical said, with commercial agreements in key markets including the European Economic Area, UK, Switzerland, South Korea, Latin America and the Middle East.
"Following the approval by the US [Food & Drug Administration] earlier this year, Mexican marketing authorisation opens up another very large and exciting market for Eroxon. Mexico is a vibrant and dynamic market, and we look forward to bringing the benefits of Eroxon to ED sufferers in Mexico with our commercial partner M8."
Futura Medical noted that erectile dysfunction disrupts the lives of at least one in five men globally, while Mexico currently has a population of around 129 million.
Shares in Futura Medical were down 1.3% to 33.32 pence each in London on Wednesday afternoon.
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Futura Medical (FUM)